AstraZeneca stock holds after 2025 revenue reaches $54.1 billion

AstraZeneca stock is tied to 2025 revenue of $54.1 billion and core earnings per share of $9.65, with the company also reporting total revenue growth of 18% year on year for 2025. The company name AstraZeneca (ISIN US6549022043) remains consistent with the US-listed identifier used here.

Revenue grew 18%

AstraZeneca reported 2025 total revenue of $54.1 billion, up 18% from 2024, and core EPS of $9.65 for the year. The same 2025 results also showed oncology sales of $20.9 billion, which made the segment the largest contributor to the group’s top line.

The 18% growth rate matters because it came on a very large base, not a start-up scale comparison. For a large-cap pharmaceutical group, that combination of size and growth is the key investor metric.

Core EPS reached $9.65

Core EPS of $9.65 in 2025 gives a second anchor for the stock story, because it links the sales expansion to earnings power. The company also said the figure reflects the full-year period ended 31 December 2025, which keeps the number firmly tied to the latest reported annual cycle.

On that same basis, oncology revenue of $20.9 billion in 2025 was the largest unit-level number in the results and remains the clearest product-line driver in the report. That makes the cancer portfolio the most visible business line behind the annual performance.

Oncology leads with $20.9 billion

Oncology is the main product group to watch because it produced $20.9 billion in 2025 revenue, alongside the wider group total of $54.1 billion. The portfolio includes major medicines such as Tagrisso, Imfinzi, Lynparza, and Calquence, which are central to the company’s commercial profile.

For readers tracking the stock, the practical takeaway is that the annual numbers already show the operating mix: revenue scale, earnings conversion, and the contribution from oncology are all visible in one set of figures.

US listing and market context

AstraZeneca is a global pharmaceutical group with a US identifier in the company input used for this article, and the stock reference here follows that listing context. The latest body-level market anchor is the 2025 annual revenue of $54.1 billion, paired with core EPS of $9.65 and oncology sales of $20.9 billion.

That combination gives a dated, evidence-based frame for the shares without relying on a speculative near-term catalyst. In practical terms, the report numbers are the main fresh valuation inputs available in this article.

Tagrisso and Imfinzi

Tagrisso and Imfinzi remain important because they sit inside the oncology segment that generated $20.9 billion in 2025. Their relevance is less about a single product update than about the scale they add to the revenue base that supports the stock narrative.

When a pharma group has one segment contributing nearly $21 billion in annual sales, the product mix can matter as much as the total revenue line. That is the case here, where oncology is not a side business but the core earnings engine.

AstraZeneca stock and the 2025 base

AstraZeneca stock is therefore best read through the 2025 base: $54.1 billion in revenue, $9.65 in core EPS, and $20.9 billion from oncology. Those three figures define the latest measurable backdrop for the shares and give investors the most concrete reference point in this article.

The stock is framed here by that annual set of numbers, not by a short-term headline move. The report period ended 31 December 2025, which makes the figures suitable as the most recent full-year operating benchmark.